BioNexus Gene Lab Statistics
Total Valuation
BGLC has a market cap or net worth of $5.00 million. The enterprise value is $1.43 million.
Important Dates
The last earnings date was Tuesday, April 14, 2026, after market close.
| Earnings Date | Apr 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BGLC has 2.42 million shares outstanding. The number of shares has increased by 4.20% in one year.
| Current Share Class | 2.42M |
| Shares Outstanding | 2.42M |
| Shares Change (YoY) | +4.20% |
| Shares Change (QoQ) | +13.38% |
| Owned by Insiders (%) | 27.46% |
| Owned by Institutions (%) | 2.08% |
| Float | 1.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.71 |
| Forward PS | n/a |
| PB Ratio | 0.61 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.46, with a Debt / Equity ratio of 0.03.
| Current Ratio | 10.46 |
| Quick Ratio | 9.00 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -158.58 |
Financial Efficiency
Return on equity (ROE) is -35.24% and return on invested capital (ROIC) is -69.20%.
| Return on Equity (ROE) | -35.24% |
| Return on Assets (ROA) | -19.68% |
| Return on Invested Capital (ROIC) | -69.20% |
| Return on Capital Employed (ROCE) | -35.49% |
| Weighted Average Cost of Capital (WACC) | 16.51% |
| Revenue Per Employee | $390,785 |
| Profits Per Employee | -$157,085 |
| Employee Count | 19 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 6.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.13% in the last 52 weeks. The beta is 2.31, so BGLC's price volatility has been higher than the market average.
| Beta (5Y) | 2.31 |
| 52-Week Price Change | -28.13% |
| 50-Day Moving Average | 2.35 |
| 200-Day Moving Average | 4.09 |
| Relative Strength Index (RSI) | 37.07 |
| Average Volume (20 Days) | 3,351 |
Short Selling Information
The latest short interest is 9,968, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 9,968 |
| Short Previous Month | 23,800 |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.57% |
| Short Ratio (days to cover) | 2.18 |
Income Statement
In the last 12 months, BGLC had revenue of $7.42 million and -$2.98 million in losses. Loss per share was -$1.61.
| Revenue | 7.42M |
| Gross Profit | 1.09M |
| Operating Income | -3.10M |
| Pretax Income | -2.98M |
| Net Income | -2.98M |
| EBITDA | -2.99M |
| EBIT | -3.10M |
| Loss Per Share | -$1.61 |
Full Income StatementBalance Sheet
The company has $4.04 million in cash and $225,525 in debt, giving a net cash position of $3.81 million or $1.58 per share.
| Cash & Cash Equivalents | 4.04M |
| Total Debt | 225,525 |
| Net Cash | 3.81M |
| Net Cash Per Share | $1.58 |
| Equity (Book Value) | 8.61M |
| Book Value Per Share | 3.56 |
| Working Capital | 4.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.84 million and capital expenditures -$36,971, giving a free cash flow of -$1.88 million.
| Operating Cash Flow | -1.84M |
| Capital Expenditures | -36,971 |
| Depreciation & Amortization | 111,873 |
| Net Borrowing | 32,305 |
| Free Cash Flow | -1.88M |
| FCF Per Share | -$0.78 |
Full Cash Flow StatementMargins
Gross margin is 14.62%, with operating and profit margins of -41.74% and -40.20%.
| Gross Margin | 14.62% |
| Operating Margin | -41.74% |
| Pretax Margin | -40.20% |
| Profit Margin | -40.20% |
| EBITDA Margin | -40.23% |
| EBIT Margin | -41.74% |
| FCF Margin | n/a |